Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of fludarabine, cytarabine, treosulfan and filgrastim in elderly patients with acute myeloid leukemia
2008-000664-16Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, cytarabine, treosulfan and filgrastim in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Disease-free survival. Started Feb 2008; status: completed.
02
Drugs
fludarabinecytarabinetreosulfanfilgrastim
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-000664-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000664-16.